These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34499340)

  • 1. Odevixibat: First Approval.
    Deeks ED
    Drugs; 2021 Oct; 81(15):1781-1786. PubMed ID: 34499340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Odevixibat and partial external biliary diversion showed equal improvement of cholestasis in a patient with progressive familial intrahepatic cholestasis.
    Slavetinsky C; Sturm E
    BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32601135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
    Baumann U; Sturm E; Lacaille F; Gonzalès E; Arnell H; Fischler B; Jørgensen MH; Thompson RJ; Mattsson JP; Ekelund M; Lindström E; Gillberg PG; Torfgård K; Soni PN
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101751. PubMed ID: 34182185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.
    Thompson RJ; Arnell H; Artan R; Baumann U; Calvo PL; Czubkowski P; Dalgic B; D'Antiga L; Durmaz Ö; Fischler B; Gonzalès E; Grammatikopoulos T; Gupte G; Hardikar W; Houwen RHJ; Kamath BM; Karpen SJ; Kjems L; Lacaille F; Lachaux A; Lainka E; Mack CL; Mattsson JP; McKiernan P; Özen H; Rajwal SR; Roquelaure B; Shagrani M; Shteyer E; Soufi N; Sturm E; Tessier ME; Verkade HJ; Horn P
    Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):830-842. PubMed ID: 35780807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Odevixibat: A Review of a Bioactive Compound for the Treatment of Pruritus Approved by the FDA.
    Porwal M; Kumar A; Rastogi V; Maheshwari KK; Verma A
    Curr Drug Res Rev; 2023 Mar; ():. PubMed ID: 36892028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maralixibat: First Approval.
    Shirley M
    Drugs; 2022 Jan; 82(1):71-76. PubMed ID: 34813049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Odevixibat (Bylvay) for progressive familial intrahepatic cholestasis-associated pruritus.
    Med Lett Drugs Ther; 2022 Feb; 64(1644):28-29. PubMed ID: 35171896
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.
    Ovchinsky N; Aumar M; Baker A; Baumann U; Bufler P; Cananzi M; Czubkowski P; Durmaz Ö; Fischer R; Indolfi G; Karnsakul WW; Lacaille F; Lee WS; Maggiore G; Rosenthal P; Ruiz M; Sokal E; Sturm E; van der Woerd W; Verkade HJ; Wehrman A; Clemson C; Yu Q; Ni Q; Ruvido J; Manganaro S; Mattsson JP
    Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):632-645. PubMed ID: 38670135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis.
    Gwaltney C; Ivanescu C; Karlsson L; Warholic N; Kjems L; Horn P
    Adv Ther; 2022 Nov; 39(11):5105-5125. PubMed ID: 36066745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Odevixibat: A Novel Bile Salt Inhibitor Treatment for Pruritus in Progressive Familial Intrahepatic Cholestasis.
    Flattmann FE; Mohiuddin FS; Singh A; Tandon A; Lockett SJ; Hirsch JD; Mosieri CN; Kaye AM; Varrassi G; Ahmadzadeh S; Shekoohi S; Kaye AD
    Cureus; 2024 Mar; 16(3):e56886. PubMed ID: 38659510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency.
    Di Giorgio A; Sciveres M; Fuoti M; Sonzogni A; Mandato C; D'Antiga L
    Clin Res Hepatol Gastroenterol; 2023 Oct; 47(8):102185. PubMed ID: 37499899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: Add-on treatment with odevixibat in a new subtype of progressive familial intrahepatic cholestasis broadens the therapeutic horizon of genetic cholestasis.
    Pepe A; Colucci A; Carucci M; Nazzaro L; Bucci C; Ranucci G; Di Giorgio A; Vajro P; Mandato C
    Front Pediatr; 2023; 11():1061535. PubMed ID: 36865697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders.
    Karpen SJ; Kelly D; Mack C; Stein P
    Hepatol Int; 2020 Sep; 14(5):677-689. PubMed ID: 32653991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paediatric research sets new standards for therapy in paediatric and adult cholestasis.
    Jeyaraj R; Maher ER; Kelly D
    Lancet Child Adolesc Health; 2024 Jan; 8(1):75-84. PubMed ID: 38006895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis.
    Kamath BM; Stein P; Houwen RHJ; Verkade HJ
    Liver Int; 2020 Aug; 40(8):1812-1822. PubMed ID: 32492754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis.
    Thompson RJ; Artan R; Baumann U; Calvo PL; Czubkowski P; Dalgic B; D'Antiga L; Di Giorgio A; Durmaz Ö; Gonzalès E; Grammatikopoulos T; Gupte G; Hardikar W; Houwen RHJ; Kamath BM; Karpen SJ; Lacaille F; Lachaux A; Lainka E; Loomes KM; Mack CL; Mattsson JP; McKiernan P; Ni Q; Özen H; Rajwal SR; Roquelaure B; Shteyer E; Sokal E; Sokol RJ; Soufi N; Sturm E; Tessier ME; van der Woerd WL; Verkade HJ; Vittorio JM; Wallefors T; Warholic N; Yu Q; Horn P; Kjems L
    JHEP Rep; 2023 Aug; 5(8):100782. PubMed ID: 37456676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Odevixibat: a promising new treatment for progressive familial intrahepatic cholestasis.
    Bedoyan SM; Lovell OT; Horslen SP; Squires JE
    Expert Opin Pharmacother; 2022 Nov; 23(16):1771-1779. PubMed ID: 36278881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Odevixibat as an adjunctive treatment for refractory pruritus in rare variants of cholestatic liver disease.
    Goel A; Tucker B; Casale LS; Grammatikopoulos T
    JPGN Rep; 2024 Aug; 5(3):296-302. PubMed ID: 39149201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microvillous Inclusion Disease: An Exceedingly Rare Condition With a New Treatment.
    Fiedler A; Brittan K; Manatsathit W
    ACG Case Rep J; 2024 Oct; 11(10):e01537. PubMed ID: 39403551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials.
    Hof WFJ; de Boer JF; Verkade HJ
    Expert Opin Emerg Drugs; 2024 Sep; 29(3):305-320. PubMed ID: 38571480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.